CRVS
Corvus Pharmaceuticals Inc
NASDAQ: CRVS · HEALTHCARE · BIOTECHNOLOGY
$15.19
+5.34% today
Updated 2026-04-30
Market cap
$1.35B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.53
Dividend yield
—
52W range
$3 – $27
Volume
1.3M
Corvus Pharmaceuticals Inc (CRVS) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $12.53M | $98.46M | $140.15M | $94.78M | $118.23M | $83.65M | $85.53M | $109.45M | $68.24M | $45.55M | $68.91M |
| Cash & equivalents | $12.52M | $4.11M | $134.90M | $90.06M | $114.60M | $5.15M | $16.45M | $63.46M | $13.16M | $12.62M | $8.74M |
| Current assets | $12.53M | $95.66M | $134.90M | $90.06M | $114.60M | $79.34M | $45.34M | $71.31M | $43.66M | $27.96M | $54.41M |
| Total liabilities | $12.69M | $129.56M | $7.35M | $9.94M | $7.90M | $12.54M | $13.38M | $12.29M | $12.13M | $6.87M | $36.34M |
| Current liabilities | $2.67M | $3.07M | $7.35M | $9.94M | $7.90M | $10.22M | $12.15M | $9.69M | $10.75M | $6.87M | $35.40M |
| Long-term debt | — | — | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Shareholder equity | $-159000.00 | $-31.10M | $132.80M | $84.83M | $110.34M | $71.11M | $72.15M | $97.16M | $56.12M | $38.68M | $32.57M |
| Retained earnings | $-161000.00 | $-31.50M | $-67.87M | $-123.53M | $-170.47M | $-217.15M | $-223.14M | $-266.38M | $-307.69M | $-334.72M | $-397.01M |
| Accounts receivable | — | $347000.00 | $365000.00 | $132000.00 | $337000.00 | $329000.00 | $86000.00 | $539000.00 | $633000.00 | $63000.00 | $216000.00 |
| Inventory | — | $722000.00 | $-1.14M | $-852000.00 | $-602000.00 | $-815000.00 | $-492000.00 | $-667000.00 | $-735000.00 | — | — |
| Goodwill | — | — | $0.00 | $0.00 | — | — | — | — | — | — | — |